Chemical Structure : RAF265
CAS No.: 927880-90-8
Catalog No.: PC-42483Not For Human Use, Lab Use Only.
RAF265 (CHIR265) is a potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $128 | In stock | |
10 mg | $188 | In stock | |
25 mg | $298 | In stock | |
50 mg | Get quote | ||
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
RAF265 (CHIR265) is a potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation.
RAF265 (CHIR265) blocks Raf-MEK-ERK signalling and significantly enhances TRAIL sensitivity in NCI-H727 and CM insulinoma cells.
RAF265 (CHIR265) inhibits cell proliferation with IC50 of 0.83-5.54 uM in CRC cells, demonstrates significant anti-tumor activity in tumors of xenograft models.
M.Wt | 518.4139 | |
Formula | C24H16F6N6O | |
Appearance | Solid | |
Storage |
|
|
Solubility |
DMSO: ≥ 26 mg/mL |
|
Chemical Name/SMILES |
1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]- |
1. Mordant P, et al. Mol Cancer Ther. 2010 Feb;9(2):358-68.
2. Zitzmann K, et al. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85.
3. Su Y, et al. Clin Cancer Res. 2012 Apr 15;18(8):2184-98.
4. Chen J, et al .Cancer Res. 2011 Jun 15;71(12):4280-91.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright